Edition:
United States

Vascular Biogenics Ltd (VBLT.OQ)

VBLT.OQ on NASDAQ Stock Exchange Global Market

2.15USD
20 Apr 2018
Change (% chg)

$-0.05 (-2.27%)
Prev Close
$2.20
Open
$2.20
Day's High
$2.20
Day's Low
$2.12
Volume
12,939
Avg. Vol
43,471
52-wk High
$9.05
52-wk Low
$2.05

Chart for

About

Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company's program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly... (more)

Overall

Beta: -1.72
Market Cap(Mil.): $64.24
Shares Outstanding(Mil.): 29.88
Dividend: --
Yield (%): --

Financials

  VBLT.OQ Industry Sector
P/E (TTM): -- 188.22 33.60
EPS (TTM): -0.39 -- --
ROI: -20.15 -0.74 13.19
ROE: -20.63 -2.80 15.00

BRIEF-VBL Therapeutics Awarded $2.5 Million Non Dilutive Grant By The Israel Innovation Authority

* VBL THERAPEUTICS AWARDED $2.5 MILLION NON-DILUTIVE GRANT BY THE ISRAEL INNOVATION AUTHORITY Source text for Eikon: Further company coverage:

Apr 09 2018

BRIEF-VBL Therapeutics Announces Top-Line Results From Pivotal Phase 3 Globe Study In Patients With Recurrent Glioblastoma

* VBL THERAPEUTICS ANNOUNCES TOP-LINE RESULTS FROM PIVOTAL PHASE 3 GLOBE STUDY IN PATIENTS WITH RECURRENT GLIOBLASTOMA

Mar 08 2018

BRIEF-VBL Therapeutics Receives Milestone Payment From Nanocarrier Under Licensing Agreement For VB-111 In Japan

* VBL THERAPEUTICS RECEIVES MILESTONE PAYMENT FROM NANOCARRIER UNDER LICENSING AGREEMENT FOR VB-111 IN JAPAN

Feb 08 2018

BRIEF-Vascular Biogenics Says Top-Line Data From Globe Phase 3 Pivotal Trial Of VB-111 Expected In Q1 Of 2018

* VASCULAR BIOGENICS - TOP-LINE DATA FROM GLOBE PHASE 3 PIVOTAL TRIAL OF VB-111 EXPECTED IN Q1 OF 2018 Source text for Eikon: Further company coverage:

Dec 27 2017

BRIEF-Vascular Biogenics Files For Mixed Shelf Of Up To $150 Mln - SEC Filing

* VASCULAR BIOGENICS LTD FILES FOR MIXED SHELF OF UP TO $150 MILLION - SEC FILING Source text: (http://bit.ly/2CY4IXN) Further company coverage:

Dec 18 2017

BRIEF-VBL therapeutics prices 2.5 mln ordinary share offering

* VBL Therapeutics prices 2.5 million ordinary share offering

Nov 17 2017

BRIEF-VBL Therapeutics announces proposed public offering of 2.5 mln shares of ordinary shares

* VBL Therapeutics announces proposed public offering of 2.5 million shares of ordinary shares Source text for Eikon: Further company coverage:

Nov 16 2017

BRIEF-VBL therapeutics Q3 loss per share $0.24

* VBL Therapeutics announces third quarter 2017 financial results

Nov 14 2017

BRIEF-VBL Therapeutics and Nanocarrier signs agreement for VB-111 in Japan

* VBL Therapeutics and Nanocarrier Co Ltd sign exclusive agreement for VB-111 in Japan

Nov 06 2017

BRIEF-VBL THERAPEUTICS OPENS NEW GENE THERAPY MANUFACTURING PLANT, HEADQUARTERS

* VBL THERAPEUTICS CELEBRATES OPENING OF ITS NEW GENE THERAPY MANUFACTURING PLANT AND COMPANY HEADQUARTERS

Oct 23 2017

Earnings vs. Estimates